Strides Pharma Science Limited (STAR) - Total Assets

Latest as of March 2026: Rs69.27 Billion INR ≈ $749.15 Million USD

Based on the latest financial reports, Strides Pharma Science Limited (STAR) holds total assets worth Rs69.27 Billion INR (≈ $749.15 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Strides Pharma Science Limited investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Strides Pharma Science Limited - Total Assets Trend (2005–2026)

This chart illustrates how Strides Pharma Science Limited's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Strides Pharma Science Limited to see how much of total assets are deployed in long-term investments.

Strides Pharma Science Limited - Asset Composition Analysis

Current Asset Composition (March 2026)

Strides Pharma Science Limited's total assets of Rs69.27 Billion consist of 52.2% current assets and 47.9% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 3.1%
Accounts Receivable Rs12.97 Billion 18.7%
Inventory Rs16.35 Billion 23.6%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs8.00 Billion 11.5%
Goodwill Rs5.94 Billion 8.6%

Asset Composition Trend (2005–2026)

This chart illustrates how Strides Pharma Science Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Strides Pharma Science Limited (STAR) total market value.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Strides Pharma Science Limited's current assets represent 52.2% of total assets in 2026, an increase from 47.1% in 2005.
  • Cash Position: Cash and equivalents constituted 3.1% of total assets in 2026, down from 4.4% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 4.0% in 2005.
  • Asset Diversification: The largest asset category is inventory at 23.6% of total assets.

Strides Pharma Science Limited Competitors by Total Assets

Key competitors of Strides Pharma Science Limited based on total assets are shown below.

Company Country Total Assets
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥14.18 Billion
SIMCERE PHARMAC. GRP LTD
F:S2P
Germany €14.73 Billion
Curaleaf Holdings Inc.
TO:CURA
Canada CA$2.88 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Walvax BioTech
SHE:300142
China CN¥11.13 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion

Strides Pharma Science Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.25 1.20 1.03
Quick Ratio 0.68 0.70 0.59
Cash Ratio 0.00 0.00 0.00
Working Capital Rs7.17 Billion Rs5.07 Billion Rs814.64 Million

Strides Pharma Science Limited - Advanced Valuation Insights

This section examines the relationship between Strides Pharma Science Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.10
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) 14.5%
Total Assets Rs69.27 Billion
Market Capitalization $1.11 Billion USD

Valuation Analysis

Below Book Valuation: The market values Strides Pharma Science Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Strides Pharma Science Limited's assets grew by 14.5% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Strides Pharma Science Limited (2005–2026)

The table below shows the annual total assets of Strides Pharma Science Limited from 2005 to 2026.

Year Total Assets Change
2026-03-31 Rs69.27 Billion
≈ $749.15 Million
+14.52%
2025-03-31 Rs60.49 Billion
≈ $654.15 Million
+3.58%
2024-03-31 Rs58.40 Billion
≈ $631.55 Million
-12.03%
2023-03-31 Rs66.38 Billion
≈ $717.92 Million
-4.84%
2022-03-31 Rs69.76 Billion
≈ $754.41 Million
-0.56%
2021-03-31 Rs70.15 Billion
≈ $758.65 Million
+14.03%
2020-03-31 Rs61.52 Billion
≈ $665.29 Million
-23.16%
2019-03-31 Rs80.06 Billion
≈ $865.77 Million
+22.34%
2018-03-31 Rs65.44 Billion
≈ $707.68 Million
-19.38%
2017-03-31 Rs81.17 Billion
≈ $877.80 Million
+5.98%
2016-03-31 Rs76.59 Billion
≈ $828.30 Million
+208.08%
2015-03-31 Rs24.86 Billion
≈ $268.86 Million
+18.44%
2014-03-31 Rs20.99 Billion
≈ $227.00 Million
-56.25%
2013-03-31 Rs47.98 Billion
≈ $518.84 Million
-12.20%
2012-03-31 Rs54.64 Billion
≈ $590.93 Million
+21.61%
2011-03-31 Rs44.93 Billion
≈ $485.94 Million
+39.12%
2010-03-31 Rs32.30 Billion
≈ $349.29 Million
+38.77%
2009-03-31 Rs23.27 Billion
≈ $251.70 Million
+14.46%
2008-03-31 Rs20.33 Billion
≈ $219.91 Million
+65.73%
2007-03-31 Rs12.27 Billion
≈ $132.69 Million
+31.10%
2006-03-31 Rs9.36 Billion
≈ $101.22 Million
+71.20%
2005-03-31 Rs5.47 Billion
≈ $59.12 Million
--

About Strides Pharma Science Limited

NSE:STAR India Drug Manufacturers - Specialty & Generic
Market Cap
$1.11 Billion
Rs102.39 Billion INR
Market Cap Rank
#8629 Global
#423 in India
Share Price
Rs1110.80
Change (1 day)
+0.35%
52-Week Range
Rs793.55 - Rs1188.10
All Time High
Rs1643.30
About

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more